The role of the EORTC pathologist in clinical trials: Achievements and perspectives

European Journal of Cancer

Volumn 38, Issue SUPPL. 4, 2002, Pages 120-124

  Spatz, Alain ^a   Ruiter, Dirk J ^b   Busch, Christen ^c   Theodorovic, Ivana ^d   Wolter Oosterhuis, J ^e  

^a INSTITUT GUSTAVE ROUSSY   (France)

^b RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^c Department of Pathology   (Norway)

^d EORTC DATA CENTER   (Belgium)

^e JOSEPHINE NEFKENS INSTITUTE   (Netherlands)

Author keywords

Clinical trials; EORTC; Oncology; Pathology; Quality control; Research

Indexed keywords

IMATINIB;

CANCER DIAGNOSIS; CARCINOGENESIS; CLINICAL RESEARCH; DISEASE COURSE; DRUG INDUSTRY; HUMAN; PARAMETER; PATHOLOGIST; PATIENT SELECTION; PRIORITY JOURNAL; PROGNOSIS; QUALITY CONTROL; REGULATORY MECHANISM; REVIEW; STROMA;

EID: 0036175698     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0959-8049(01)00445-2     Document Type: Review

References (40)

1. Cell locomation and tumour penetration. Report on a workshop of the EORTC cell surface project group
2. Stage I melanoma of the skin: Evaluation of prognosis according to histologic characteristics
3. Estrogen receptor status and response to polychemotherapy in advanced breast cancer
4. EORTC protocols in prostatic cancer. An interim report
5. An assay for estradiol preceptors using a staphylococcal protein-A - Estradiol antibody adsorbent
6. Quality assurance in surgical oncology (QASO) within the European Organisation for Research and Treatment of Cancer (EORTC): Current status and future prospects
7. Pathology data in the central databases of multicenter randomized trials need to be based on pathology reports and controlled by trained quality managers
8. Central pathology review in clinical trials for patients with malignant glioma. A report of Radiation Therapy Oncology Group 83-02
9. Variations in diagnostic and therapeutic procedures in a multicentre, randomized clinical trial (EORTC 10853) investigating breast-conserving treatment for DCIS
10. Melanoma in childhood: An EORTC-MCG multicenter study on the clinico-pathological aspects
11. Prognostic factors in patients with pleural mesothelioma: The European Organisation for Research and Treatment of Cancer experience
12. Prognostic factors in primary cutaneous large B-cell lymphomas: A European multicenter study
13. Primary cutaneous lymphomas
14. EORTC classification for primary cutaneous lymphomas: A comparison with the R.E.A.L. Classification and the proposed WHO Classification
15. EORTC classification for primary cutaneous lymphomas: The best guide to good clinical management. European Organisation for Research and Treatment of Cancer
16. EORTC classification for primary cutaneous lymphomas: A proposal from the Cutaneous Lymphoma Study Group of the European Organisation for Research and Treatment of Cancer
17. Histopathological grade and response to chemotherapy in advanced soft tissue sarcomas
18. Prognostic index for extremity soft tissue sarcomas with isolated local recurrence
19. Prognostic factors in head and neck soft tissue sarcomas
20. Clinico-pathological data and prognostic factors in completely resected AJCC stage I-III liposarcomas
21. Histologic prognostication in soft tissue sarcomas: Grading versus subtyping or both? A comprehensive review of the literature with proposed practical guidelines
22. Prognostic factors for the outcome of chemotherapy in advanced soft tissue sarcoma: An analysis of 2,185 patients treated with anthracycline-containing first-line regimens - A European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group Study
23. Ductal carcinoma in situ of the breast from a population-defined cohort: An evaluation of new histopathological classification systems
24. Quality assurance of pathology in clinical trials. The National Surgical Adjuvant Breast and Bowel Project experience
25. Papillary and follicular thyroid carcinoma. Individualization of the treatment according to the prognosis of the disease
26. Is the EORTC prognostic index of thyroid cancer valid in differentiated thyroid carcinoma? Retrospective multivariate analysis of differentiated thyroid carcinoma with long follow-up
27. The EORTC melanoma group translational research program on prognostic factors and ultrastaging in association with the adjuvant therapy trials in stage II and stage III melanoma. European Organisation for Research and Treatment of Cancer
28. Immunohistochemical detection of steroid receptors in breast cancer: A working protocol. UK Receptor Group, UK NEQAS, The Scottish Breast Cancer Pathology Group, and The Receptor and Biomarker Study Group of the EORTC
29. Twenty years of experience with the steroid receptor External Quality assurance program - The paradigm for tumour biomarker EQA studies
30. What the clinician needs from the pathologist: Evidence-based reporting in breast cancer
31. The EORTC Melanoma Group exchange program: Evaluation of a multicenter monoclonal antibody study
32. The utility of mitotic index, oestrogen receptor and Ki-67 measurements in the creation of novel prognostic indices for node-negative breast cancer
33. Angiogenesis is an independent prognostic factor in malignant mesothelioma
34. High tPA-expression in primary melanoma of the limb correlates with good prognosis
35. Prognostic factors in bladder carcinoma: Histologic parameters and expression of a cell cycle-related nuclear antigen (Ki-67)
36. p53 protein accumulation and response to adjuvant chemotherapy in premenopausal women with node-negative early breast cancer
37. Expression of gp100, MART-1, tyrosinase, and S100 in paraffin-embedded primary melanomas and locoregional, lymph node, and visceral metastases: Implications for diagnosis and immunotherapy. A study conducted by the EORTC Melanoma Cooperative Group
38. Synergistic effects of TNF-alpha and melphalan in an isolated limb perfusion model of rat sarcoma: A histopathological, immunohistochemical and electron microscopical study
39. Clinical applications of INF-alpha in cancer
40. An experimental inter-expert telepathology network using static imaging